Professor Giuseppe Mazza co-founded Engitix and has served as Chief Executive Officer (CEO) since the Company’s formation in 2016.

Engitix was established to build on and commercialise Giuseppe’s pioneering research which resulted in a proprietary human extracellular matrix ECM drug discovery platform. His foundational/initial research was carried out in the laboratory of co-founder, Professor Massimo Pinzani at the Institute for Liver and Digestive Health (ILDH), Division of Medicine, University College London (UCL).

As CEO, Giuseppe has led the company through significant growth including several rounds of financing and secured significant partnerships with Dompei, Takeda and Morphic, as well as establishing new cutting-edge bespoke laboratories and offices at WestWorks, White Park, London.

Previously, Giuseppe was a Post-Doctoral Fellow at the UCL ILDH, where he was also responsible for operating the Tissue Engineering and Regenerative Medicine Laboratory. He received his PhD in Tissue Engineering and Organ Regeneration from UCL. He still maintains an affiliation with UCL as Honorary Associate Professor. Giuseppe also served as a Director R&D at Promethera Bioscience from 2015 to 2017.

He has been involved in several international healthcare organizations, including serving on the Steering Committee of the non-profit European Haemophilia Consortium (EHC). In 2011, he founded the healthcare charity Associazione Icore ONLUS, where he served as President for six years.